Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026
ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and Provides Conference Call Information Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, NJ – August 13, 2026: Elite P
How this was made
The 30-second read
Why it matters
The filing itself is a disclosure event and sets expectations for the Aug 14 conference call, but the provided excerpt does not include the actual financial results or any forward-looking guidance.
Market read
This is primarily a procedural disclosure update tied to quarterly results; actionable trading depends on the missing Exhibit 99.1 and the 10-Q details.
What to watch
Traders should verify Exhibit 99.1 and the attached 10-Q for any revenue, margin, cash balance, debt, or outlook changes that are not present in the scraped text.
Background
The SEC 8-K reports Item 2.02 results of operations and financial condition, referencing a quarterly Form 10-Q for the first quarter ended June 30, 2026 and a press release furnished as Exhibit 99.1.
Ticker impact
Elite Pharmaceuticals filed its quarterly 10-Q results for the first quarter ended June 30, 2026 and scheduled a follow-up conference call Aug 14.
Near-term volatility is possible around the underlying 10-Q/press-release details, but this specific text alone is unlikely to drive a directional move.
The article confirms the existence/timing of the quarterly results and call, yet does not include the actual earnings numbers, outlook, or any discrete event beyond disclosure mechanics.
Market effects
Limited signal for the broader pharma sector because the excerpt contains no drug, trial, or regulatory catalyst.
None indicated.
None indicated.
Counterpoint
If the omitted exhibit (press release) contains material beats/misses or guidance changes, the trading impact could be higher than this excerpt suggests.
Key entities
- issuerElite Pharmaceuticals, Inc.
OTCQB-listed company filing an 8-K for quarterly results and scheduling a conference call.
- executiveNasrat Hakim
President and CEO signing the 8-K.
